Title: Treatment of alopecia universalis with topical Janus Kinase inhibitors – a double blind, placebo and active controlled pilot study

Short title: Treatment of Alopecia Areata with topical JAK inhibitors.

Keywords: Tofacitinib, ruxolitinib, clobetasol, JAK, JAK inhibitors, alopecia areata

Authors:
Laita Bokhari (MPhil Med)
Rodney Sinclair (MBBS, MD, FACD)

Corresponding author:
Prof Rodney Sinclair
2 Wellington Parade
East Melbourne, VIC 3002
Email: Rodney.sinclair@sinclairdermatology.com.au

Funding Source:
A research project grant from the Australia Alopecia Areata Foundation

Conflicts of interest: None

Manuscript word count: 1356 (excluding abstract and references)
Table count: 1
Figure count: 5
Abstract

Background Oral Janus Kinase (JAK) inhibitors are currently being investigated in phase II and phase III clinical trials for several inflammatory skin diseases including alopecia areata (AA). Topical JAK inhibitors have been investigated in atopic dermatitis, psoriasis and alopecia areata. While a number of case series using topical JAK inhibitors in AA have been published, to date there have been no randomized controlled clinical trials.

Methods We conducted a phase 1, 28-week prospective, placebo-controlled, double-blind study in patients with alopecia universalis investigating hair regrowth with 2 topical JAK inhibitors, ruxolitinib 2% and tofacitinib 1%. Topical clobetasol dipropionate 0.005% was used as an active comparator while vehicle was used as the placebo control. 16 patients were recruited for the study.

Results Six patients demonstrated partial hair regrowth in areas treated with 2% tofacitinib ointment applied twice daily. Five patients demonstrated partial hair regrowth in the areas treated with 1% Ruxolitinib ointment while ten patients demonstrated partial hair regrowth in the areas treated with clobetasol dipropionate 0.05% ointment. No regrowth was observed in the placebo treated area. Interestingly, generalised hair regrowth was observed in two patients. One patient had 100% regrowth over his entire scalp and eyebrows by week 24 but relapsed after 12 weeks. A second patient also experienced generalised scalp regrowth and significant eyebrow growth and continued to maintain growth 14 weeks later.

Conclusion Our findings suggest that topical JAK inhibitors could be developed as a potential new treatment for AA and alternative to clobetasol dipropionate 0.05% ointment.

Word Count: 248
Introduction

Alopecia Areata (AA) is a chronic, relapsing and remitting, inflammatory disease of terminal anagen hair follicles. AA produces one or more lesions of complete hair loss ranging in severity from a small thumbprint-sized bald patches to total baldness of the scalp or universal loss of every terminal hair on the body (1, 2). The lifetime risk of alopecia areata is 1.7% and 10% of affected individuals develop severe disease as defined by >50% hair loss. Persistent moderate-to-severe AA causes significant disfigurement and psychological distress in affected individuals (3-5). There are no evidence-based treatments for AA (4), yet various treatments are offered, most commonly topical and intralesional steroids, which have limited efficacy.

AA has a complex polygenetic aetiology and more than 17 gene polymorphisms have been identified in population gene association studies. These genes polymorphisms implicate in both innate and adaptive immune responses.

The pathogenesis involves activation of the Janus Kinase and signal transducer and activator of transcription (JAK/STAT) inflammatory pathway, collapse of hair bulb immune privilege and subsequent autoimmune attack of the hair bulb by IFN-γ–producing NKG2D-bearing CD8+ cytotoxic T lymphocytes (6, 7) (Figure 1).

There are 4 JAK isoforms; JAK1, JAK2, JAK3 and Tyrosine Kinase-2. Activated CD8+ NKG2D+T releases IFN-γ which bind to receptors on the hair follicle bulb, resulting in an increased signalling of JAK1 and JAK2. This promotes the production of IL-15, a regulator of T and natural killer cell activation and proliferation, which binds to its receptor on the CD8+ T cell surface. This subsequently results in increased signalling of JAK1 and JAK3, further enhancing the production of IFN-γ (Figure 2). This positive feedback loop was described by Divito and Kupper in 2014 (8).
Therapeutic targeting of Janus Kinase (JAK) in AA, has been shown to reverse AA in C3H/HeJ mice (9) as well as adult and adolescent humans (10-13). Ruxolitinib and tofacitinib are small-molecule JAK inhibitors that work on both hair follicles and on CD8+ NKG2D+T cells. Ruxolitinib is an oral dual inhibitor of the JAK1 and 2 enzymes that is currently FDA and TGA approved for the treatment of myeloproliferative disorders. Tofacitinib is an oral inhibitor of the JAK 3 enzyme that is currently FDA and TGA approved for the treatment of rheumatoid arthritis. Both these inhibitors have been shown to alleviate the symptoms of AA.

Tofacitinib in a dose of 5mg twice daily orally has been shown in phase II clinical trials to be effective in the treatment of psoriasis and atopic dermatitis (10, 12, 14, 15). Tofacitinib 2% ointment applied twice daily and Ruxolitinib1% ointment applied twice daily have both been examined in phase I clinical trials in the treatment of psoriasis and tofacitinib intra-ocular eye drops have been trialled for the treatment of iritis. No safety issues were identified with either ointment or eye-drop preparations.

While there have been a number of case series reporting hair regrowth following treatment of alopecia areata with topical JAK inhibitors, to date, there have been no placebo controlled, double blind studies examining hair regrowth with topical JAK inhibitors in patients with AA universalis.

We conducted an investigator initiated, 28-week, prospective, double-blind placebo controlled, pilot study comparing Ruxolitinib 1% ointment and Tofacitinib 2% ointment to clobetasol dipropionate 0.05% ointment (active comparator) to ointment base (placebo).
Methods

This study was approved by Epworth Healthcare Ethics Committee (HREC No.672-15). All procedures and visits were conducted in accordance with The International Conference on Harmonisation's (ICH) Guideline for Good Clinical Practice (GCP).

The study duration was 28 weeks with a 12-week treatment period followed by another 12-week follow-up period after the last dose. Volunteers with alopecia universalis were supplied with 4 tubes of ointment. The first tube was labelled right eyebrow. The second tube was labelled left eyebrow. The third tube was labelled right temple and the forth tube was labelled left temple. Subjects were instructed to apply the ointment to each designated area twice a day. The pharmacist used a random number generator to determine which ingredient was in each tube. Neither the subjects nor clinical investigators knew which ingredient was in each tube.

Qualitative assessment of the efficacy of topical JAK inhibitors were determined by changes in global photography, 4-point scale for investigator’s and patient’s global assessment (IGA and PtGA respectively) at baseline and over time up to the final visit (Week 0 2, 4, 6, 8, 12, 18, 24). Qualitative assessment of changes in hair growth was monitored through global photography on a standardised photography equipment. Photographs of patient’s scalp vertex and frontal scalp were captured at every visit and assessed by an independent assessor. The description for the 4-point scale for IGA and PtGA are as follows: 1 denotes poor/no growth/no non-vellus hair observed; 2 denotes fair or sparse growth of vellus hair observed in treatment areas; 3 denotes good or considerable growth of non-vellus and terminal hair observed in treatment areas and 4 denotes very good, excellent or significant regrowth of terminal hair observed in treatment areas. IGA was performed by the same physician at all visit to maintain consistency of reported outcomes.
Results

16 patients with a clinical diagnosis of Alopecia Universalis were enrolled in the study. Six patients demonstrated partial hair regrowth in the area treated with 2% Tofacitinib ointment applied twice daily. Five patients demonstrated partial hair regrowth in the area treated with 1% Ruxolitinib ointment applied twice daily. Ten out of 16 patients demonstrated partial hair regrowth in the areas treated with clobetasol dipropionate 0.05% ointment applied twice daily. Regrowth was observed as early as 4 weeks following commencement of treatment.

Interestingly, two patients developed generalised hair regrowth on the scalp and eyebrows during the treatment period that went beyond the area of ointment application. Qualitative assessments of global photographs are represented in Figures 3-5. Patient 1 began presenting with regrowth on the scalp six weeks following the first application of the study medication and progressed to a full head of hair by the last application (Figure 3). The hair regrowth reversed within the 12-week follow-up period. This hair regrowth and eventual fall out may be attributed to the inhibitory role of the JAK inhibitors. After completion of the trial, Patient 1 was commenced on oral tofacitinib 5 mg daily and achieved complete hair regrowth over a 9-month period (Figure 4). In contrast, Patient 2 continued to demonstrate generalised hair regrowth 14 weeks after the last topical application without further medication (Figure 5).

While regrowth was seen in the placebo area in 2 patients, both patients experienced generalised regrowth over their entire scalp. No patient experienced regrowth just in the placebo treated area or in the area treated with just the active comparator.

No dermal atrophy or side-effects were identified hence the topical application of JAK inhibitors is considered safe. In addition, patient’s blood pressure, physical examination and safety assessments were conducted throughout the duration of the study. No significant findings were reported.
Conclusion

Our findings suggest that topical use of the JAK inhibitors, tofacitinib and ruxolitinib may have a role in the treatment of AA. Response rates are likely to be improved by use of higher concentrations of the active ingredient or vehicles that enhance penetration into the dermis. Based on findings with oral JAK inhibitors in AA, we also believe that a longer duration of JAK inhibition will increase the response rate. It is likely that prolonged treatment will be required to maintain response.

In essence, the generalised regrowth could be a result of the systemic synergistic effect of the topical absorption of ruxolitinib, tofacitinib and clobetasol. Specifically, this would be the transient suppression of the JAK enzymes by tofacitinib and ruxolitinib and enhancement by Clobetasol. It may be beneficial to study the effect of topical JAK inhibitors with separate placebo and treatment groups in order to investigate the individual effect of each medication. Additionally, the depigmented regrowth we observed have been previously documented elsewhere in AA patients (16-18).

Finally, pharmacokinetic studies that measure tissue and serum concentrations following topical application of JAK inhibitors should be employed to guide the development of topical JAK inhibition treatment of AA.

Acknowledgements

This work was supported by a research grant by the Australia Alopecia Areata Foundation.
References

Graph 1. Average change of hair regrowth based on IGA. Gradual improvement in regrowth was observed up to Visit 8 (End of treatment) using a 4-point scale. Areas treated with 0.05% Clobetasol showed the most significant improvement in regrowth followed by 2% Tofacitinib.
Table 1. Investigator’s global assessment of hair regrowth in Patients 1 & 2 across the 24-week study. The most significant observed improvement in regrowth was reported at Visit 8 coinciding with the end of treatment (EOT) visit. * indicates end of topical application of study medications.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Visit 1 (Screening)</th>
<th>Visit 2 (Wk 0/SOT)</th>
<th>Visit 3 (Wk 2)</th>
<th>Visit 4 (Wk 4)</th>
<th>Visit 5 (Wk 6)</th>
<th>Visit 6 (Wk 8)</th>
<th>Visit 7 (Wk 10)</th>
<th>Visit 8 (Wk 12/EOT)</th>
<th>Visit 9 (Wk 18/FU1)</th>
<th>Visit 10 (Wk 24/FU2)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A - 1% RUXOLITINIB</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>P2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td><strong>B - 2% TOFACITINIB</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>P2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td><strong>C - 0.05% CLOBETASOL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>P2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>4</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td><strong>D - PLACEBO</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>P2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>

1 = poor/no growth/no non-vellus hair observed; 2 = fair/sparse growth of vellus hair observed in treatment areas; 3 = Good/considerable growth of non-vellus and terminal hair observed in treatment areas; 4 = very good/excellent/significant regrowth of terminal hair observed in treatment areas.
Figure 1. Proposed pathogenesis of Alopecia areata. Cytokines and cellular factors thought to be responsible for maintaining immune privilege such as TGF-β1 and IGF-1 are listed in the left box. Factors such as Substance P and IFN-γ believed to mediate loss of immune privilege and subsequently initiation of disease are listed in the middle box. Loss of immune privilege is associated with increased expression of MHC class I molecules, which are capable of presenting hair follicle autoantigens to T lymphocytes. Consequently, autoimmune events that may result in the amplification of the pathology of AA including activation of CD4+ T cells are listed in the right box. Image courtesy of Gilhar et al (2007) (19).
Figure 2. Positive feedback loop in Alopecia areata. Xing et al. showed that CD8+ NKG2D+ T cells infiltrate the dermis and localize to the hair follicle bulb, forming immune synapses with follicular epithelial cells through major histocompatibility complex (MHC) class I–peptide complexes and NKG2DL. Activated CD8+ T cells release IFN-γ binding to its receptor on the surface of the follicular epithelial cell. This in turn signals JAK1 and JAK2 to promote production of IL-15, a mediator of CD8+ T cell induction, and its chaperone IL-15Rα. This binds the IL-15R complex (IL-2Rβ and γc) on the CD8+ T cell surface, causing signaling via JAK1 and JAK3 to enhance the production of IFN-γ and amplify the feedback loop. Ruxolitinib and tofacitinib are small-molecule JAK inhibitors that interfere with this feedback loop. Ruxolitinib inhibits JAK1 and JAK2 while tofacitinib inhibits JAK3 more strongly than JAK1. Both these inhibitors have been shown to alleviate the symptoms of Alopecia areata. STAT1, signal transducer and activator of transcription-1; TCR, T cell receptor; STAT5, signal transducer and activator of transcription-5. Extracted from Divito et al 2014.
Figure 3. Patient 1 demonstrated a full regrowth by the end of the 12-week topical treatment period. Generalised regrowth was observed over the scalp. Facial hair was also reported by patient.

Figure 4. Complete regrowth following nine months of treatment with oral tofacitinib 5mg daily.
Figure 5. Patient 2 demonstrated significant regrowth by the end of the 12-week treatment period and progressively continued regrowth up to 14 weeks after the last topical application of the study medication.